REG - Eco Animal Health Gp - EU launch plans for ECOVAXXIN® MS

ECO Animal HealthAnnouncement

26/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260226:nRSZ4414Ua&default-theme=true

RNS Number : 4414U  Eco Animal Health Group PLC  26 February 2026

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

EU launch plans for ECOVAXXIN® MS

 

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, provides an update on its commercial launch
strategy for ECOVAXXIN® MS, its poultry vaccine
against Mycoplasma synoviae, across the European Union (EU).

 

Following the European Commission granting marketing authorisation for
ECOVAXXIN® MS, announced in December 2025
(https://tools.euroland.com/tools/PressReleases/GetPressRelease/?ID=7852080&lang=en-GB&companycode=services)
, ECO's management team are progressing a detailed commercialisation plan
designed to deliver strategic market entry across key European territories
throughout 2026 and 2027.

 

ECOVAXXIN® MS clinical need

ECOVAXXIN® MS provides active immunisation of future layer and breeder
chickens from four weeks of age, helping to reduce air-sac and foot-pad
lesions and egg production losses caused by Mycoplasma synoviae infections.
 The infection causes economic loss, especially in laying hens, and the
number of eggs produced by affected layers can be reduced by 5-10%.

 

The launch positions ECO as a comprehensive Mycoplasma solutions provider,
combining best-in-class prevention through ECOVAXXIN® MS with market-leading
treatment via its lead product Aivlosin®.

 

Go-to-market strategy

ECO Animal Health will leverage its existing comprehensive commercial network,
successfully built for Aivlosin®, for the commercialisation of ECOVAXXIN®
MS, taking advantage of deep expertise and customer reach in established
distribution channels, and supplementing where necessary with additional
technical and geographical capabilities.

 

The Company has secured agreements with key strategic distribution partners
providing comprehensive coverage across the EU's major poultry markets. These
partnerships provide access to markets representing over 220 million layer
birds annually across the EU's top seven layer-producing countries.

 

"This launch represents a significant milestone as the first product from
ECO's proprietary R&D pipeline to be commercialised. We have developed a
differentiated vaccine that addresses real producer need, with extensive
technical support capabilities that have proved highly valuable to our
Aivlosin customers," said David Hallas, Chief Executive Officer of ECO Animal
Health. "We look forward to updating the market on our progress as we move
through our commercial launch plans over the coming months and later across
different territories."

 

Phased launch strategy

The ECOVAXXIN® MS pre-launch phase, currently underway, comprises distributor
training programmes, technical assessment completion, establishment of
distribution agreements, marketing, and customer segmentation activities
across key markets.

 

An official launch event will be held from 30 June to 1 July 2026 in Madrid,
Spain, bringing together key opinion leaders, genetics companies, major layer
producers and distribution partners from across Europe. This will be followed
by several regional launch events between Q3 2026 and Q1 2027 targeting key
layer-producing countries.

 

Financial impact

The Company expects sales of ECOVAXXIN® MS to be immediately margin accretive
and anticipates a material contribution to EBITDA from the product's sales for
the 2027/2028 financial year.

 

Andrew Buglass, Chief Commercial Officer of ECO Animal Health, said:
"Following the receipt of EU marketing authorisation for ECOVAXXIN MS over a
month ahead of schedule, we are on track to execute our comprehensive and
well-structured launch plan for ECOVAXXIN MS across the EU. Our training
programmes are being rolled out and our marketing materials are in final
preparation for our launch event in June. With a best-in-class product,
coupled with strategic enhancements to our established EU commercial network,
we are well positioned for successful market entry."

 

 

-Ends-

 

Contacts

 

 ECO Animal Health Group plc                                    020 8447 8899

 David Hallas (Chief Executive Officer)

 Christopher Wilks (Chief Financial Officer)

 ICR Healthcare (Financial PR)                                  020 3709 5700

 Mary-Jane Elliott

 Jessica Hodgson
 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Philip Davies

 Jalini Kalaravy

 Samed Ethemi

 Panmure Liberum (Joint Broker)                                 020 3100 2000

 Emma Earl

 Will Goode

 Mark Rogers

 Rupert Dearden

 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

 

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

 

Our lead product, Aivlosin(®) is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

 

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSEAESIEMSEEE



            Copyright 2019 Regulatory News Service, all rights reserved